DDInter556 DDInter1094
Dihydrocodeine is an opioid analgesic used as an alternative or adjunct to codeine to treat moderate to severe pain, severe dyspnea, and cough. It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis. It was marketed in 1911.
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Galantamine
Galantamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Morphine
Morphine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Oxycodone
Oxycodone {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Galantamine
Galantamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Tofacitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Morphine
Morphine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Tofacitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Oxymorphone
Oxymorphone {u} (Compound) resembles {v} (Compound) Oxycodone
Oxycodone {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Oxycodone
Oxycodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lorlatinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Hydrocodone
Hydrocodone {u} (Compound) resembles {v} (Compound) Galantamine
Galantamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Dextromethorphan
Dextromethorphan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Valdecoxib
Valdecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Morphine
Morphine {u} may lead to a major life threatening interaction when taken with {v} Oxazepam
Oxazepam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Dihydrocodeine (Compound) resembles Galantamine (Compound) and Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Dihydrocodeine (Compound) resembles Morphine (Compound) and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Dihydrocodeine (Compound) resembles Oxycodone (Compound) and Oxycodone may lead to a major life threatening interaction when taken with Lorlatinib
Dihydrocodeine (Compound) resembles Galantamine (Compound) and Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Dihydrocodeine (Compound) resembles Morphine (Compound) and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Dihydrocodeine (Compound) resembles Oxymorphone (Compound) and Oxymorphone (Compound) resembles Oxycodone (Compound) and Oxycodone may lead to a major life threatening interaction when taken with Lorlatinib
Dihydrocodeine (Compound) resembles Oxycodone (Compound) and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Dihydrocodeine (Compound) resembles Hydrocodone (Compound) and Hydrocodone (Compound) resembles Galantamine (Compound) and Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Dihydrocodeine (Compound) resembles Dextromethorphan (Compound) and Dextromethorphan may cause a minor interaction that can limit clinical effects when taken with Valdecoxib and Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Dihydrocodeine (Compound) resembles Morphine (Compound) and Morphine may lead to a major life threatening interaction when taken with Oxazepam and Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib